Previously known as the penny dreadful Savoy Equities
Anyone going for a punt?
http://www.stuff.co.nz/business/indu...matory-product
Printable View
Previously known as the penny dreadful Savoy Equities
Anyone going for a punt?
http://www.stuff.co.nz/business/indu...matory-product
and little liquidity.
The record date for the SPP was yesterday, so you needed to have bought on or before the 22nd.
The 'good news' announcement was not until the afternoon of the 22nd, so at least it is difficult to say that they tried to spruik it.
It could be the next PEB, if that can be considered as a good thing.
Best Wishes
Paper Tiger
"We compared it to some natural, and even some synthetic, anti-inflammatory products out there and we are pretty much beating them all," Daily said.
This statement doesn't exactly inspire much confidence...
PIL have done a lot of prep work over several years, and are finally looking like they might have a better mousetrap. The company has hired a new CEO who has knowledge of and connections in the US healthcare market. Who knows where this one will go, but arthritis, and inflammation generally, is a huge potential market so might be worth a punt.
Disc, have a few, not worth much though.
Half year results out now. A bigger loss due to increased setting up costs. Revenue from sales almost doubled from last half year, though still quite small. Arthrem is only sold in NZ so far but a lot of work happening to develop the US market.
Might not have recalled correctly, but I think their base product was originally trialed as a natural anti malarial and the arthritis aspect unexpectedly popped out of those trials.
As mentioned above, hold a few, mainly to support a local Wellington initiative.
Announced today:
Publication of Peer-Reviewed Research Paper on Arthrem(TM)
Mr Malcolm Johnson, Chairman of Promisia Integrative Limited announced today the publication of a peer-reviewed scientific research paper. The paper's
first author is the company's Principal Scientist Dr Sheena Hunt. The research paper was published by the Journal of Inflammation Research, a
recognised and authoritative international journal.
The published results show that the primary ingredient of Arthrem(TM), Promisia's proprietary plant extract, has potent anti-inflammatory activity
in vitro. Concentrations as low as 0.05% completely inhibited production of the inflammatory mediator tumour necrosis factor-alpha. The extract was also
a strong inhibitor of the cyclooxygenase (COX) inflammatory marker, prostaglandin E2.
Small but pretty interactive PIL annual meeting earlier this week. There was an announcement beforehand relating to a randomised, double-blind, placebo-controlled, 12 week trial at the Rheumatology Research Unit, University of Otago, which was partially funded by Callaghan Innovation. This produced statistically significant results on the benefits of Arthrem and is to be published in a peer reviewed journal. A version of the product for canine arthritis is underway - fur babies is a potentially lucrative market. The company is positioning its products as rigorously tested / trialled - rather unusual in NZ's fairly unregulated nutritional supplements market.
Arthrem has been quietly launched in the US (arthrem.com) with the intention of selling on a subscription basis worldwide. A surprisingly small number of subscriptions is required to be profitable.
Artemis, what is a "fur baby"? And what do you get on a "subscription basis"? Arthrem capsules? Shares?
I assume from your name that you have a connection with Artemisia Annua.
I have a bottle of Arthrem in my medicine cabinet. After taking it for 3 months I am not sure that it helped me. But still willing to talk about it, maybe not so willing to pay for it.
Fur baby - common name for a pet treated like one of the family. I used it rather tongue in cheek to indicate that folk with fur babies often spend big on them, as they would for a human child.
Subscription is for capsules.
No, my user name is complete coincidence, and relates to the Greek myth. I am a shareholder, however, and was one long before this product was even thought of.
The Principal Scientist at PIL said the Rheumatology Research Unit was very pleased with the results.
As I type this, another coincidence, NBR Radio is broadcasting quite a lengthy item on PIL and Arthrem.
Half year report to 30 June released. Link below. Projections suggest cash flow positive by end of 2016. Capital raising coming. Also coming 3 new products in the pipeline.
Interesting that artemisia annua is the basis for the malaria treatment which has just got a Nobel prize. PIL was pursuing the malaria angle when they found that folk in those trials got arthritis relief.
Extract
Sales in New Zealand are exceeding budgets and growing. There has been
a large increase in the average monthly sales since May 2015 when the company
announced the positive preliminary clinical trial findings. Sales of the company’s
flagship product Arthrem® have increased by more than 150% compared to the
previous 12 month average monthly sales.
The company has had some sales success in the United States but is awaiting
publication of its clinical trial results before embarking on a concerted public relations
campaign. The US e-commerce platform is fully operational and a soft launch in June
exceeded budget. Promisia is testing various offerings in an effort to determine the
most effective sales strategy. The US market represents the greatest opportunity
for Promisia to increase revenues. The market is approximately 90 times larger
than New Zealand and it carries with it a higher level of discretionary spending.
http://www.promisia.com/financial-reports.
Bit of action lately. Rights issue which was flagged has kept a lid on the price. But this will lift soon I guess. Quite a good announcement from the chairman yesterday confirming publication of the Clinical Trials in an international medical journal called Clinical Rheumatology. Those outfits are widely read and followed by the professionals. Due diligence should include visiting a pharmacy or two and just asking about the stuff.
I think this will be a big year for PIL coming up . Turning cashflow positive, breaking into USA and Australia market on a bigger scale. Enough cash in the bank to get them on the way now for some serious growth.
Couple of updates from the recent annual shareholder meeting.
A lot of effort has gone into supporting and upgrading the online global sales platform.
Plenty of TV ads (using real people not actors) and this is boosting sales (revenue more than the ad spend). Good idea to trial in NZ which is usually regarded as a good test bed. Plus there was an article earlier this year about a young cyclist who took Arthrem with good results, and sales spiked.
An independent pharmacy sales company told PIL recently that Arthrem was the fastest moving single product in pharmacies in the June quarter.
Canine version of Arthrem not ready for release yet. So far only palatable for 70% of breeds, which is too low, they are working on it.
PIL have stopped NZ pharmacies from selling Arthrem via their websites as the information given was not what PIL wanted) not sure why). Plus PIL margin is better if they sell direct from the PIL website. Seems like a mistake to me. Surely a problem which has been solved many times.
Overall they are optimistic about revenue and thus share price. We'll see, but they do seem to be laying very good groundwork.
Joined today whoever else is trying to buy at 0.023c The marketing model seems good to me having been in that game myself 24 years now! There will be a point of critical mass where things start to roll along positively without so much "forcing" , or even completely go off! Gotta be in for the chance of that. :t_up: Discl. I got first bad dose of hip-socket arthritis a year ago!
Hmmm, suddenly there's a bit of a run on the SP... Is the Half Year results out tomorrow? Perhaps someone has a whiff of what's coming...
I can understand that, in that retailers get lazy about generating sales in-store. Then all that happens is a price-war gets going across the net. The supplier wants the brick-n-mortar store to capture the people in their neighbourhood with the product.
Interesting that last time I went to local pharmacy for a prevent cold/flue remedy they chucked an Arthrem pamphlet in the bag: Perfect! Strategy is working. ;-)
Seems whoever they have got on-board, or from outside, directing their marketing they are quite good! ...it is a very tough (precision required) game in the small market (pop.n) of NZ!
I see that last year's report was released 4.30pm last Friday in August so expect the same again - tomorrow. Could be the next BLT!
Someone is manipulating jumping it to 27 when offers at 23, 24, 25! I'm not offering anymore!
Finally got my offer: Really pleased to be into this (at right price) even if it takes a while to become a serious stock. Now I'm a holder intend sharing biz ideas with them direct! (but as mentioned, think they have someone good on-board in the marketing game) Next sales reports will be the tell-all. If what I'm picking this stock could go amongst the best;-)
Good news for Promisia, still a penny stock but maybe not such a 'penny dreadful' now. Another loss but nearly a million in sales, and apart from NZ target markets are barely touched yet. It was mentioned at the recent ASM that sales revenue in NZ exceeds the advertising spend. I see a lot of TV and internet advertising.
Sounds like Arthrem for dogs is well on the way, with the palatibility issue apparently sorted. Could be a lucrative global market as it is a natural product, and cheaper than a visit to the vet plus prescription.
And a hint of another product with a clinical trial begun.
:t_up: someone just made me 28% better off today LOL. Already thinking to increase my holding. Cripes, if they go to a dollar next couple years I could retire! ...ride my MT-bike more! ;-) A million sales is poor really: It's the turn-over barely good enough for a one-man-band. We'll know they're worth something when they get to TEN mill in sales which they need to get to pronto to stretch out time that they'll get "run over" by competitors! IMHO.
QUOTE:
"as at 08:30:27, Tuesday 30 August, 2016 (NZT)HALFYR: PIL: 600% sales increase for Promisia
PIL
30/08/2016 08:30
HALFYR
PRICE SENSITIVE
REL: 0830 HRS Promisia Integrative Limited
HALFYR: PIL: 600% sales increase for Promisia
Report of the Chairman and Chief Executive
The Chairman and Chief Executive are pleased to report the Half Year Report
for Promisia Integrative Limited and its subsidiaries ("the Group") for the
six month period ended 30 June 2016.
Sales
We are pleased to report healthy sales of $994,098 for Arthrem which is
$850,000, or 600%, more than the sales of $142,000 for the same period in
2015.
According to IRI-AZTEC scan pharmacy data, Arthrem is the fasting growing
brand and product, in dollar terms, for 2016. It also ranks 13th among
brands in dollar terms in pharmacy for New Zealand.
Australia
The company is making good progress towards the launch of Arthrem in
Australia. Arthrem is now manufactured in a Therapeutic Goods of Australia
(TGA) compliant facility with Good Manufacturing Practice certification.
This is an important step, and a prerequisite, to becoming a listed
complementary medicine in Australia. The listing will allow Arthrem to make
stronger evidence-based therapeutic claims in its advertising. Current
legislation prevents these claims being made in New Zealand.
United States of America
Sales in the US continue to grow. Cash spend in the US is being managed
carefully by testing different digital marketing models and using real time
measurement of their effectiveness.
Arthritis supplement for dogs
The major challenge for developing an arthritis supplement product for dogs
using the Group's unique plant extract has been masking the distinctive
pungent smell and bitter taste. Unlike humans, who can swallow a capsule
whole, dogs will smell and chew capsules. Therefore a soft gel capsule is
not an option.
The company's Principal Scientist, Dr Sheena Hunt, has developed a
formulation that masks both the smell and taste of the extract, and is
palatable to dogs. Manufacturing trials are underway.
Financial Results
The $354,000 loss for the Group for the half year, compared to $575,000 for
2015 same period, is slightly below what was expected due to the delayed
expenditure for the launch of Arthrem in Australia and the completion of
development and launch of the arthritis supplement for dogs. Much of this
budgeted expenditure will be incurred in the second half of the year. The
loss includes exchange rate movements, interest expenses, amortisation of the
company's automated marketing website and 50% of known non-cash charges such
as the share option costs.
Research
The focus of the research programme for the first half of the year has been
the development of a palatable formulation for dogs. The company is also
researching other possible therapeutic applications for its extract. A
clinical trial has just started for another product.
Outlook
Promisia will continue to promote Arthrem aggressively in the New Zealand
market. The company is confident that it will exceed its 2016 objective of
capturing at least 3% of the potential New Zealand 305,000 person
osteoarthritis market before the end of the year.
Other priorities for the second half of the year include:
o Listing Arthrem as a complementary medicine in Australia
o Preparation for the launch of Arthrem in Australia in early 2017
o Completion of development and testing of the supplement for dogs
o Preparation of a product launch and marketing campaign for a dog arthritis
treatment in New Zealand and Australia
o Ongoing refinement of the marketing strategy in the US
On behalf of the directors and management we thank shareholders for their
continued support for the company.
End CA:00288096 For:PIL Type:HALFYR Time:2016-08-30 08:30:27"
Quote from above: "...3% of the potential New Zealand 305,000 person osteoarthritis market before the end of the year."
Think i'll just "put this away in the draw" until end of year and they post improved sales.
In the meantime have banged my small holding to a sell at 5c flat. Guess I'll know there's positive action if someone kindly more than doubles my money!
;)
Been watching this for a few weeks. Its filling the gap nicely, and seems to be good support buying around 3 cents.
QUARTER: PIL: Significant Sales Growth Continues
The Directors of Promisia Integrative Limited (NZX:PIL) are pleased to advise
that sales for the third quarter of the current financial year ending 30
September 2016 have maintained the trend set in the first half year as
detailed in the company's announcement of it half year results on 30 August
2016. Sales for the third quarter were $833,009, which is a 590% increase on
sales in the same quarter in 2015.
Sales for the first 9 months of 2016 have been $1,827,009 compared with sales
of $262,716 for the same period in 2015, which is a 595% increase.
The directors are considering a modest capital raising to fund the marketing
of Arthrem in Australia in 2017 and the launch in 2017 of the canine
arthritis product in New Zealand and Australia.
This holder very happy today
Tiny amount of dollars though.
The canine version could be a winner. Plenty of owners will do whatever it takes to help their pets. Whereas human doctor visits and drugs may be subsidised that is not the case with vet bills and drugs. So although Arthrem might not be a cheap alternative for humans, it probably is for dogs. With the bonus of being natural.
Yep agree that the dollar amounts may be tiny but they are growing week by week and the chart looks good.
People who took up their rights earlier this year at 1 cent should be feeling pleased that they did. 1 cent to 4 cents....nothing else on the NZX touches that this year. And its not even a mining exploration stock.
PIL
11/11/2016 10:23
GENERAL
PRICE SENSITIVE
REL: 1023 HRS Promisia Integrative Limited
GENERAL: PIL: Year to Date Sales Exceed $2 million
The directors of Promisia Integrative Limited are pleased to advise that
total sales for the first 10 months of the year have exceeded $2 million.
Sales for the month of October exceeded $300,000 for the first time.
Final sales for the month of October were $325,587 from all sources but
mainly from sales in New Zealand. Sales for the 10 months to 31 October 2016
were $2,152,596, which is a 574% increase over same period sales in 2015.
For further information please contact:
Mr Stephen Underwood, Chairman, on 04 499 3412 or 027 499 3387
Mr Charles Daily, Chief Executive Officer, on 04 894 8524 or 021 643 906
End CA:00292523 For:PIL Type:GENERAL Time:2016-11-11 10:23:23
Wow, floated at 50 c back in the day, it does remind me of BLIS THAT FLOATED AT $1 .
my concern is that there is basically one product, with one scientist. If she got run over, what would happen to the company?
They must have things in place for that sort of thing ?
Any thoughts
Not just good for arthritis but cancer too...... Now this would be a good marketing strategy.......
"Research to develop antimalarial drugs led to the discovery of artemisinin, a compound which is extracted from Artemisia annua,( same plant that PIL use )
. It is proven, that artemisinin has anti-cancer activity as well, because it contains an endoperoxide group. Artemisinin has a high anti-cancer activity due to its interaction with iron complexes[37] in the blood. This shows that artemisinin derivatives induce apoptosis( death of ) of cancer cells as well.[38]"
not holding yet, but plan on some.
wow, lola. Not sure how to take that. :-)
i don't have any problem. I was just going to edit my post re Dr Hunt as there are obviously alot of others there, and it was a silly comment. Thankyou.
So far they are just working with one thing , but as they say in their reports, they will be developing other things once Arthrem has established its place in the market.
Re the "cancer fix", no they haven't said anything about that , but plenty of other research papers have, regarding the same plant that Arthrem is extracted from. My point was that there may be some possibility to explore that . There are lots of supporting evidence the Artemisia annua plant is useful for various thing including malaria etc
DYOR
thanks for your comment .hope you make lots of money on this one. It it goes back up to 50c we will.
chart is looking good, as is the price action for the last two days. The announcements have been well 'timed' on the pullbacks. Theres not alot on offer...
I don't believe PIL will say anything about cancer unless / until there is very good published evidence. That is not the way they do things. Not to say Arthrem won't be 'discovered' by a different market - it's what the internet does best. Perhaps PIL buyers see an opportunity. 22% up today.
The company has a contracted supply of raw material and a process for high quality extraction. So, well positioned as percy would say.
Yesterday in the last hour of trading (or so) the SP suddenly spiked up to .05c. I thought it rather odd at the time and now today I see a news release re a new rights issue saying,
"Under the offer, the company’s shareholders can apply for one New Share for every 10 Existing Shares held at 5.00pm on Friday, 25 November 2016, at $0.03 per new share. The company’s shares last traded at $0.050 per share."
The coincidence of yesterdays late afternoon rise and today's press release would seem to be pretty questionable IMHO.
"The coincidence of yesterdays late afternoon rise and today's press release would seem to be pretty questionable IMHO."
If you have a spare wet bus ticket, you could send it to the NZX. They'll know what to do.
"Dietary supplements maker and 'penny dreadful' Promisia Integrative was the outright winner on the broader NZX market with a 248% price gain"
Their advertising in NZ sells more product than it costs. That bodes well for other markets, with Australia next off the block.
http://www.nbr.co.nz/article/year-re...est-rates-rise
Thanks Artemis. SP MAY MOVE UP AGAIN NOW THE Share offer was over subed. My wish list was scaled down to 20 %.ish so well over subscribed . I consider then more of a natural medicine, than dietary supplement ... Maybe , probably , i think .........
I think there are restrictions in NZ as to what products can be called, and what claims can be made about them. Australia has different categories which allow more claims to be made.
And I agree it is more a natural medicine. 2015 Nobel prize for medicine was won for use of artemisia annua extract to treat malaria. IIRC Promisia's first foray into this product was for malaria. The initial trials came up with a surprise finding - participants reported arthritis improvement. And the rest, as they say, is history (we hope).
Thanks for that helpful post. Shall we take some fish oil with that from NZK .? New listing looks interesting . Have a good new year. Im off to get some sun.
Valuation looks rich if the sales growth stalls. If they can maintain the growth (even better, the growth in growth) then this will look very cheap in another 18-24 months. Just need to watch for sales numbers when announced.
Wondering if anyone else out there has tried it, any feedback on the efficacy? I'm less concerned with what it's called, than whether it can consistently have an effect on general population... ?
I use it. It has a good affect and I bought more shares on the reports I heard from the physio and chemist.
I've spoken to a Doctor that uses it , but also a mother in law who couldn't stomach it.
Since there was an over subscription of shares, what happen is they scale everyones order back until it reaches the amount that they wanted to issue initially, you only pay for what you got and nothing more. You will get your funds back to the details you proved, that or they send you a whole lot of Arthrem to make up for it ;)
Refund received --used it to top up yesterday. Nice little bonus rise today. ...Happy to hold
Best to approach this as almost a VC type investment at this point. I'd be surprised if there was a positive NPAT this FY. But I think PIL is Op CF positive now which is the first step. I'm looking to buy more if we come back into low 5c range before the next ann (which I'm assuming will be that sales growth is continuing to be strong, though unlikely to be as strong as last ann which was 5-600% or some such). Whenever I ask about the product in pharmacies the staff tell me it is moving well. Price point feels high to me though.
We might see people take profits from the .03c placement so i think the SP will fall a bit more. There do seem quite a few sellers v buyers for the last week or so. Then we might pick up a few more.
QUARTER: PIL: 4th QTR Sales - Significant Growth Continues
The Directors of Promisia Integrative Limited (NZX:PIL) are pleased to advise that sales for the third quarter of the current financial year ending 31 December 2016 have maintained the trend set throughout 2016 year as detailed in the company's previous quarterly sales announcements. Sales for the fourth quarter were $842,576, which is a 485% increase on sales in the same quarter in 2015. Sales for the full 12 months of 2016 are $2,668,068 compared with sales of $406,644 for the same period in 2015, which is a 556% increase. The company also traded profitably for the 4th quarter of 2016, and will report the full year's annual report in due course. An independent report shows that Arthrem is currently the No.1 Single selling product in NZ Pharmacies in dollar terms.
Sales momentum seems to be stalling?
3rd Q - $833,009
4th Q - $842,576
Is there seasonality to this drug? Sufferers suffer less during warmer months?
Suspect there is a seasonal effect. Osteoarthritis runs in my family, and I remember my mother having to soak her hands in warm water to get them moving on cold mornings. (Anecdata.)
PIL has been doing a huge amount of TV advertising here, and obviously have found that sales revenue exceeds advertising cost. That bodes well for similar advertising in other markets, Australia probably next off the block. It would be interesting to find out how many are repeat sales and how many one off. It is the repeat sales that are important for ongoing revenue.
Hard to know the answer yet. EG were the Q3 sales a group which bought several months worth of product, meaning a large chunk of Q4 sales were new to the product OR were the majority of Q3 sales the same people who were also buying in Q4, in which case the product has already reached a level of market saturation? Also, the potential for seasonal effect is certainly there. Also, we don't know much about vendor inventories - were they building up in Q3 and running down in Q4, which would tell us something quite different from if it were the opposite.
The bigger concern for me is the cheerleading tone of the announcement. It is obvious that Q4 sales were not significantly greater than Q3, so why not discuss that, and the Directors response to this fact, rather than apparently ignore it?! We are here speculating on the possible reasons for something instead of getting some informed views on it.
well, looks like the market ha had time to digest the news..
Not sure the volume is large enough to infer anything about the 'market'. Either way, slow drift down feels like a reasonably likely outcome until we see FY results. Key will be timeline to FY profitability (FY18?) and where the next stage of revenue growth is coming from (Aust? US? Pet Food?). Is anyone planning to attend any planned public presentation?
There needs to be some real growth in the pipeline to justify even current market cap. That said, full disc., I like the product, still hold.
Unaudited financials released this week (Dec FY). Confirmed a few positives, in particular it looks like Arthrem is viable and the business is profitable on a run-rate basis (ie looks like profitable each month on current sales volume). A few weird/disappointing things: announcement that Jan was ahead of Jan '16 (completely irrelevant for early stage growth business, question is how the company is doing month-on-month); no timeline on Australian registration or finalising the dog product (just noted as 'priorities' for 2017).
Next couple of quarters sales will be really interesting. I wonder how much upside there is in NZ on current strategy if Arthrem is already the 'top-selling product, by dollar value'. Sales don't need to grow at last years rate but do need to grow significantly to justify current valuation. If growth in NZ stalls or falls to single digits and there are further delays in Aust then another cap raise is certainly possible.
I sound too negative - these are just watch points. Overall I think this is a great story and the company is doing an excellent job so far. I'm just wary of current valuation. Still holding.
https://www.nzx.com/companies/PIL/announcements/298173
Now why would the CEO resign suddenly and with immediate effect?
Something does not smell right.
First the Chairman stepped down, and then resigned as a director shortly after.
May 2016 : "Mr Malcolm Johnson, Chairman of Promisia Integrative Limited has stepped down
as the Company's Chairman. Mr Johnson said "The Company has a clear strategic direction and an exciting
product in Arthrem which already has a considerable following and is capable of aiding many more arthritis sufferers with other products in the pipeline". Mr Johnson commented that the Company had a bright future and that during his three year tenure he had put in place a suite of best practice governing documents which would stand the Company in good stead."
Then, the CEO steps down.
If there is more upside, why would they be resigning?
Wonder if they are selling or have already gotten rid of some of their shares to cash in on the millions of dollars of gains they are sitting on?
4 years is a good tenure for a CEO these days. I agree with Balance, responsible officers cannot just dump their stock when they leave. If you look at what he has done in the past , its been about start up, and move on. Now, hes probably got substantial holdings in Wholly Bagels, and Promisia... and is off looking for the next iron in the fire....
Just my opinion.
Valuation coming back to something reasonable. Depending on how Q1 sales look relative to Q4 I'm thinking it might be worth buying a few more. New CEO needs to be solid but realistically we're not looking for the next Jack Welch - just someone competent with some marketing/retail/supply chain experience.
https://www.nzx.com/companies/PIL/announcements/299990
Hmmmm - 24% decline in 1Q 17 sales vs 4Q 16 sales.
There goes the growth story.
"The quarterly sales of $643,588 were up by 169% from the same period in 2016."
The growth story has not gone entirely.
However, I agree the departure of the CEO and Chairman is a major concern until we see news of replacements and the planned new products and Australia launch, there is a HUGE need for caution around this company as indicated by the Market's 50% reduction in the SP from last years highs.
I sold out as there is a competitive product available at half the price
The quarter that sales go backwards from a previous quarter is when the company will be marked down by investors whose definition of growth stock is one of sales increases consecutively quarter to quarter.
Too coincidental that CEO and Chairman decided to 'retire/quit' imo.
The chemist told me the Arthri Remedy were half price and that is correct, furthermore they appear to me to have a better distribution chain.Maybe the management changes were because of no brand protection by PIL.
In my opinion they are as good and a 50% lower price is a good selling point and as I say the GO distribution channel looks better. Its half the price for what I think is at least as good a product and it must affect PIL sales,
Horus I have no axe to grind either way, but you sound like a snake oil salesman's dream. You haven't given a reason why it's as good but you sure do like the price...but wait, there's more....buy 3 more by the time you're finished reading this post and receive 12 months worth absolutely free...oops times up...never mind buy 2 at twice the normal price and receive a third for half the double price!!!! Unbelievable value!!!!
Surely pil are snake oil salesmen themselves....max advertising...fund the only scientific research out there...high share price...sell your shares.
Then release the canine product...repeat advertising...make money off emotionally challenged dog owners...job done
Or am i being overly flippant!?
I am pretty cold when it comes to losing money on shares. I have sold out , kept a few for interest but they have dropped since I got out. I have a big portfolio and am used to having small co , high risk shares, my instinct tells me these will have cash flow problems in the future .TIL are different , they have good distribution and their products are getting more established.
Have a look at the capsules and they state as follows:
Arthrem - Each capsule contains 150 mg standardized extract of Artemisia annua plus grape seed oil to enhance natural absorption.
Arthri-Remedy - Each capsule contains artemisia annua extract 5400mg.
Try and make sense of it if you can!
Artemisia Annua is the name of the plant and the active ingredient of the plant is artemisinin,
I would think Arthrem contains the standardized extract Artemisinin.
We're as Arthri Remedy just contains the the whole plant material.
i personally think its a case of apples and oranges, and without a scientific evaluation who would know. Go Healthy NZ have a large range of Products. Promisia are focused on one. Possibly Go Healthy are piggy backing off the back of the success of arthrem. Bound to happen.. If o have the choice between coca-cola and supermarket brand cola... i will buy the coca cola ....
An encouraging step towards the Australian Market...... early days tho'.
Arthrem listed as a complementary medicine in Australia
The directors of Promisia Integrative Limited announced today that the
dietary supplement, Arthrem, has been listed as a complementary medicine with
the Therapeutic Goods Administration in Australia.
Current rules in New Zealand prevent manufacturers of dietary supplements
from making any therapeutic claims, even if there is clinical evidence of
such efficacy. The regulations are different in Australia, as Chief Scientist
Dr Sheena Hunt explains, "Listing as a complementary medicine allows us to
make evidence-based claims in our advertising and marketing. This means that
in Australia we can refer to our published clinical trial evidence that
Arthrem can reduce pain and stiffness associated with osteoarthritis."
According to the Australian Government's Institute of Health and Welfare,
more than 2.1 million people in Australia (approximately 9% of the
population) suffer from osteoarthritis.